See related Cubicin powd for inj information 
Manufacturer AstraZeneca 
Distributor Hong Kong: Zuellig/Macau: Four Star 
Contents Daptomycin
Indications Treatment of complicated skin & skin structure infections (cSSSI) caused by susceptible isolates of the following gm+ve microorganisms: S. aureus (including methicillin-resistant isolates), Strep pyogenes, Strep agalactiae, Strep dysgalactiae subsp equisimilis & Enterococcus faecalis (vancomycin-susceptible isolates only); S. aureus bloodstream infections (bacteremia), including right-sided endocarditis caused bymethicillin-susceptible & -resistant isolates.
Click to view Cubicin detailed prescribing infomation
Dosage cSSSI 4 mg/kg by IV infusion in 0.9% NaCl inj over a 30-min period once every 24 hr for 7-14 days. S. aureus bloodstream infections 6 mg/kg by IV infusion in 0.9% NaCl inj over a 30-min period once every 24 hr for a min of 2-6 wk. Patient w/ renal impairment CrCl <30 mL/min, including those on hemodialysis or CAPD 4 mg/kg (cSSSI) or 6 mg/kg (S. aureus bloodstream infections) once every 48 hr.
Click to view Cubicin detailed prescribing infomation
Overdosage View Cubicin overdosage for action to be taken in the event of an overdose.
Contraindications Hypersensitivity to daptomycin.
Click to view Cubicin detailed prescribing infomation
Warnings For additional cautionary notes to warn of the potential risk of using the medicine... click to view Cubicin detailed prescribing infomation
Special Precautions Not indicated for treatment of pneumonia; renal impairment; pregnancy & lactation.
Click to view Cubicin detailed prescribing infomation
Adverse Drug Reactions Constipation, nausea, diarrhea, vomiting, inj site reactions, headache, insomnia & rash.
View ADR Monitoring Form
Drug Interactions Limited experience on use w/ warfarin & HMG-CoA reductase inhibitors.
View more drug interactions with Cubicin
Pregnancy Category (US FDA)      
     
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). 
Storage View Cubicin storage conditions for details to ensure optimal shelf-life.
Description View Cubicin description for details of the chemical structure and excipients (inactive components).
Mechanism of Action View Cubicin mechanism of action for pharmacodynamics and pharmacokinetics details.

Presentation/Packing
Form Packing Photo
Cubicin powder for injection  Cubicin 500 mg/10 mL x 1's 

Manufacturer: AstraZeneca
 
Distributor: Hong Kong: Zuellig

Macau: Four Star